GlaxoSmithKline has posted top-line results from the Phase III trial of darapladib in adults with chronic coronary heart disease (CHD). The study did not meet the primary endpoint measure, which was time to first occurrence of any major adverse cardiovascular event (MACE) from the composite of myocardial infarction (heart attack), stroke, and cardiovascular death. There were greater reductions in some of the pre-defined secondary endpoints that require further analysis. Additional data will be f...